Optimizing Management of Metastatic Pancreatic Cancer
Estimated Time to Complete Educational Activity
In this web-based program, physicians will learn how recent developments in multimodal therapies have advanced the management of metastatic pancreatic cancer.
December 5, 2017
December 5, 2019
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period December 5, 2017 through December 5, 2019 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 7 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.
Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Supported by an educational grant from Ipsen.
This activity has been planned and implemented in accordance with accreditation requirements and policies of the This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Program Faculty and Disclosure
EDWARD M. WOLIN, MD
Director, Neuroendocrine Tumor Program
Montefiore Einstein Center for Cancer Care
Montefiore Medical System
Albert Einstein College of Medicine
New York, NY
Advisory Board: Advanced Accelerator Applications, Novartis, Lexicon
ANDREA WANG-GILLAM, MD, PhD
Associate Professor of Medicine
Washington University School of Medicine
Clinical Director, Gastrointestinal Oncology Program
Siteman Cancer Center
St. Louis, MO
Advisory Board: Ipsen, Merrimack
JOHANNA BENDELL, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nothing to disclose
GEORGE KIM, MD
21st Century Oncology of Jacksonville
Consultant and Speaker’s Bureau: Ipsen, Celgene
Upon completion of this activity, participants will be able to:
- Detail the epidemiology, burden, and clinical challenges associated with detecting, diagnosing and classifying metastatic pancreatic adenocarcinoma and pancreatic neuroendocrine tumor (panNET)
- Outline the recently issued, Spring 2017 NCCN clinical practice guidelines for metastatic pancreatic adenocarcinoma and pancreatic neuroendocrine tumor (panNET); and, therefore, become more clinically proficient at applying these evidence-?based guidelines to the from lines of GI oncology practice
- Determine which patients with metastatic pancreatic cancer are appropriate for the use of surgical interventions (resection), medical therapy, and/or systemic chemotherapy, based on presentation, symptoms, tumor types and stage, clinical profiles, extent of disease, biomarkers, and other factors
- Deploy evidence-?based, guideline-?adherent therapies treatments for patients with metastatic pancreatic adenocarcinoma, including such regimens based on gemcitabine, FOLFIRINOX, nanoliposomal irinotecan, and other agents; and how to sequence them in the context of multimodal -? surgical and chemotherapeutic -? approaches to comprehensive management of pancreatic carcinoma
- Deploy evidence-?based, guideline-?adherent therapies treatments for patients with panNET, including the use of somatostatin analogs (SSAs) for symptom relief and antiproliferative properties, radiolabeled SSAs, cytotoxic drugs, angiogenesis inhibitors, and other therapies
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.